Group 1 - The article highlights that three public funds, namely ICBC Credit Suisse Fund, Yongying Fund, and E Fund, have reported paper losses from their locked shares in recent private placements, totaling approximately 6.6 million yuan [1][2] - Specifically, ICBC Credit Suisse Fund has a loss of about 296.07 thousand yuan, Yongying Fund has a loss of approximately 249.02 thousand yuan, and E Fund has a loss of around 114.76 thousand yuan [1][2] - The funds participated in one or more private placement projects, with the number of locked stocks being 1 for ICBC Credit Suisse and Yongying Funds, and 3 for E Fund [1][2] Group 2 - The data indicates that ICBC Credit Suisse Fund invested 24.477 million yuan in a private placement for Aibo Medical (688050.SH), with the lock-up period starting on May 12, 2025, and ending on November 13, 2025 [3] - Yongying Fund also participated in the same private placement for Aibo Medical, investing 20.587 million yuan, with identical lock-up dates [4] - E Fund engaged in two private placements, including Aibo Medical and Zhongtung High-tech (000657.SZ), investing 9.4871 million yuan in Aibo Medical, with the same lock-up period [5] Group 3 - The article notes that the primary source of the current public fund losses is linked to the private placement investments, which inherently carry risks due to the lock-up periods and market volatility [6] - It is mentioned that the attractiveness of private placements for companies is diminishing, as they may incur higher costs compared to other financing methods, such as debt financing, which does not dilute existing shareholders' equity [7] - Current market conditions, including low interest rates for bank loans and bond issuances, further reduce the incentive for companies to opt for private placements [7]

Meeting Overview - The shareholders' meeting of Aibo Medical was held on June 19, 2025, at the company's headquarters in Beijing [1] - A total of 238 ordinary shareholders attended, holding 79,668,669 voting rights, which represents 41.2801% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with high support, including: - Proposal 1: 79,255,028 votes in favor (99.4807%) [1] - Proposal 2: 79,258,590 votes in favor (99.4852%) [1] - Proposal 3: 79,222,750 votes in favor (99.4402%) [1] - Proposal 4: 79,269,768 votes in favor (99.4993%) [1] - Proposal 5: 36,828,822 votes in favor (98.8358%) [1] - Proposal 6: 79,222,617 votes in favor (99.4401%) [1] Board Elections - The following individuals were elected as non-independent directors: - Jie Jiangbing [3] - Wang Zhao [3] - Jia Baoshan [3] - Chen Yong [3] - Zhang Jian [3] - The following individuals were elected as independent directors: - Wang Jing [3] - Li Xunhu [3] - Wang Dongsheng [3] Legal Compliance - The meeting's procedures and voting were confirmed to comply with relevant laws and the company's articles of association by the witnessing lawyers [3]

Group 1 - The legal opinion letter confirms that the 2024 annual general meeting of Aibono Medical Technology Co., Ltd. was convened and conducted in accordance with relevant Chinese laws and regulations, as well as the company's articles of association [3][4][6] - The meeting utilized a combination of on-site and online voting, with the on-site meeting held at the company's headquarters and online voting available on June 19, 2025, from 9:15 AM to 3:00 PM [3][4] - A total of 238 shareholders participated in the voting, representing 79,668,669 shares, which accounts for 41.2801% of the total voting shares [4][6] Group 2 - The meeting's agenda included 12 proposals, with specific focus on the annual reports, financial budget, and the election of board members, including both independent and non-independent directors [6] - Proposals 11 and 12 were subject to cumulative voting, and all candidates were successfully elected [6] - The special resolution regarding the cancellation of the supervisory board and amendments to the articles of association was passed with more than two-thirds of the voting shares in favor [6]

爱博诺德（北京）医疗科技股份有限公司 章 程 二〇二五年六月 | 第一章 | 总则 4 | | --- | --- | | 第二章 | 经营宗旨和范围 5 | | 第三章 | 股份 5 | | 第一节 | 股份发行 6 | | 第二节 | 股份增减和回购 8 | | 第三节 | 股份转让 9 | | 第四章 | 股东和股东会 10 | | 第一节 | 股东 10 | | 第二节 | 股东会的一般规定 13 | | 第三节 | 股东会的召集 18 | | 第四节 | 股东会的提案与通知 20 | | 第五节 | 股东会的召开 22 | | 第六节 | 股东会的表决和决议 25 | | 第五章 | 董事会 29 | | 第一节 | 董事 29 | | 第二节 | 独立董事 34 | | 第三节 | 董事会 36 | | 第四节 | 董事会专门委员会 40 | | 第六章 | 经理及其他高级管理人员 45 | | 第七章 | 财务会计制度、利润分配和审计 47 | | 第一节 | 财务会计制度、利润分配 47 | | 第二节 | 内部审计 51 | | --- | --- | | 第三节 | 会计师事务所的聘任 5 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-041 爱博诺德（北京）医疗科技股份有限公司 关于选举董事长、董事会专门委员会委员及聘任公司 高级管理人员、证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日召开职工代表大会选举产生了第三届董事会职工代表董事，并于 2025 年 6 月 19 日召开 2024 年年度股东会，选举产生了第三届董事会非职工代表董事， 共同组成公司第三届董事会，任期自 2024 年年度股东会审议通过之日起三年。 同日，在股东会完成董事会换届选举后，公司召开第三届董事会第一次会议， 分别审议通过了《关于选举公司第三届董事会董事长的议案》《关于选举公司第 三届董事会专门委员会委员的议案》《关于聘任公司高级管理人员的议案》和 《关于聘任公司证券事务代表的议案》，选举产生了董事长和董事会各专门委员 会委员，并聘任公司新一届高级管理人员及证券事务代表。现将具体情况公告如 下： 一、选举 ...

爱博诺德（北京）医疗科技股份有限公司 关于变更注册资本、修订《公司章程》并办理工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 19 日召开第三届董事会第一次会议，审议通过了《关于变更注册资本、修订< 公司章程>并办理工商变更登记的议案》。根据公司 2020 年年度股东大会、2023 年年度股东大会以及 2024 年年度股东会对董事会的授权，本次修订《公司章程》 并办理工商变更登记无需再次提交公司股东会审议。现将有关情况公告如下： 一、公司注册资本变更情况 （一）公司根据中国证券监督管理委员会《关于同意爱博诺德（北京）医疗 科技股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕774 号），向 8 名特定对象发行人民币普通股（A 股）股票 3,593,615 股，并于 2025 年 5 月 12 日在中国证券登记结算有限责任公司上海分公司办理完毕股份登记手续。 公司的注册资本由人民币 189,544,528 元 ...

FANGDA PARTNERS http://www.fangdalaw.com 中国北京市朝阳区光华路一号 电子邮件 E-mail: email@fangdalaw.com 北京嘉里中心北楼 27 层 电 话 Tel.: +86-10-5769 5600 邮政编码：100020 传 真 Fax.: +86-10-5769 5788 27/F, North Tower, Beijing Kerry Centre 1 Guanghua Road, Chaoyang District Beijing 100020, PRC 上海市方达（北京）律师事务所 关于爱博诺德（北京）医疗科技股份有限公司 2024 年年度股东大会的法律意见书 上海市方达（北京）律师事务所（以下简称"本所"）是具有中华人民共和国 境内法律执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席爱 博诺德（北京）医疗科技股份有限公司（以下简称"公司"）2024 年年度股东大 会（以下简称"本次股东大会"），并就本次股东大会的召集和召开程序、参与表 决和召集会议人员的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中华 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-040 爱博诺德（北京）医疗科技股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 6 月 19 日 （二） 股东会召开的地点：北京市昌平区科技园区兴昌路 9 号爱博医疗公司总 部 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 238 | | --- | --- | | 普通股股东人数 | 238 | | 2、出席会议的股东所持有的表决权数量 | 79,668,669 | | 普通股股东所持有表决权数量 | 79,668,669 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 41.2801 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 41.2801 | （ ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index (Sci-Tech Medical, 950255) reported at 737.03 points, indicating a recent performance trend with a 1.84% increase over the past month, a 2.05% decrease over the past three months, and a 1.64% increase year-to-date [1] - The index comprises no more than 30 listed companies in the medical sector from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index is based on a reference date of December 30, 2022, with a base point of 1000.0 [1] Group 2 - The top ten weightings in the index are as follows: Huatai Medical (11.45%), United Imaging (10.09%), Aibo Medical (6.94%), Yirui Technology (6.44%), Nanwei Medical (5.44%), Shengxiang Biology (5.0%), Xinmai Medical (4.74%), Haier Biomedical (4.22%), Yahui Long (3.61%), and Aohua Endoscopy (3.52%) [1] - The index's holdings are entirely from the Shanghai Stock Exchange, with a 100.00% representation [1] - The industry composition of the index holdings includes 45.39% in medical consumables, 33.24% in medical devices, and 21.37% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be handled according to calculation and maintenance guidelines [2]

爱博医疗 2024 年年度股东大会会议资料 0 爱博医疗 2024 年年度股东大会会议资料 | | | | 2024 年年度股东大会会议须知 | 2 | | --- | --- | | 2024 年年度股东大会会议议程 | 4 | | 议案一：《关于<2024 年度董事会工作报告>的议案》 | 6 | | 议案二：《关于<2024 年度监事会工作报告>的议案》 | 13 | | 议案三：《关于<2024 年度财务决算报告>的议案》 18 | | | 议案四：《关于<2024 年年度报告>及摘要的议案》 27 | | | 议案五：《关于 2025 年度公司董事薪酬的议案》 | 28 | | 议案六：《关于 2025 年度公司监事薪酬的议案》 | 29 | | 议案七：《关于<2025 年度财务预算报告>的议案》 30 | | | 议案八：《关于续聘 2025 年度审计机构的议案》 | 33 | | 议案九：《关于取消公司监事会、修订<公司章程>、修订及制定部分内控制度 | | | 的议案》 | 34 | | 议案十：《关于 2024 年年度利润分配方案的议案》 | 35 | | 议案十一：《关于董事会换届选举第 ...